Kynam Capital Management’s enGene Therapeutics ENGN Stock Holding History

Kynam Capital Management’s Portfolio ENGN Stock Details ENGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$792K	Sell	457,855 -898,988	-66%	-$3.67M	0.04%	31
2026 Q1	$9.24M	Sell	1,356,843 -136,055	-9%	-$1.21M	0.57%	28
2025 Q4	$13.5M	Sell	1,492,898 -3,501,192	-70%	-$28.1M	0.86%	24
2025 Q3	$34.1M	Hold	4,994,090	–	–	2.54%	12
2025 Q2	$18.2M	Hold	4,994,090	–	–	1.96%	15
2025 Q1	$22.4M	Hold	4,994,090	–	–	1.88%	16
2024 Q4	$33.2M	Buy	4,994,090 +3,257,863	+188%	+$25.3M	1.96%	15
2024 Q3	$11.5M	Buy	+1,736,227	New	+$12.9M	0.88%	19

Other funds holding ENGN

FIS

FCPM III Services Naarden, Netherlands $750M AUM 127.27% 1-Year Est. Return

BCM

BML Capital Management Zionsville, Indiana $176M AUM 123.21% 1-Year Est. Return

Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return

Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return

ACM

ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return

VPC

Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

ACA

Acorn Capital Advisors New York $366M AUM 474.6% 1-Year Est. Return

PLC

Peapod Lane Capital Bedford Hills, New York $148M AUM 89.92% 1-Year Est. Return

Kynam Capital Management's ENGN Position: Q2 2026 in Review

Kynam Capital Management reduced its enGene Therapeutics (ENGN) stake by 66% in Q2 2026, selling an estimated $3.67M and leaving 457,855 shares worth $792K. The position accounts for 0.04% of the portfolio, ranked #31.

Kynam Capital Management first reported a position in ENGN in Q3 2024 and has held it in 8 quarters since. The position peaked at $34.1M in Q3 2025. 60 funds tracked by Wall St. Rank hold ENGN as of Q2 2026.

Kynam Capital Management held 457,855 shares of enGene Therapeutics worth $792K as of Q2 2026.
Kynam Capital Management sold 898,988 enGene Therapeutics shares in Q2 2026, an estimated $3.67M.
enGene Therapeutics made up 0.04% of Kynam Capital Management's portfolio in Q2 2026, its #31 holding.
Kynam Capital Management first reported a position in enGene Therapeutics in Q3 2024 and has held it in 8 quarters since.
Kynam Capital Management's enGene Therapeutics position peaked at $34.1M in Q3 2025.
60 funds tracked by Wall St. Rank held enGene Therapeutics as of Q2 2026.

Based on Kynam Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.